Asciminib Shows Early Promise as Frontline Therapy for CML-CP
Early results appear promising for frontline asciminib in patients with chronic phase chronic myeloid leukemia, according to researchers.
Diagnosis & Disease Information
Tyrosine Kinase Inhibitor Discontinuation Safe in Pediatric Chronic Myeloid Leukemia
Researchers sought to determine if discontinuation of TKI therapy was safe for pediatric patients with CML.
Illegitimate Online Pharmacies May Put Cancer Patients at Risk
Illegitimate online pharmacies are selling imatinib without a prescription, making false claims about being registered with regulatory bodies, and failing to provide patients with drug-related warnings.
Guidelines for CML Not Followed in the Real World
“Excellent” overall survival is achievable with currently available drugs, according to researchers.
Leukemia Treatment Regimens: Chronic Myeloid Leukemia (CML)
View detailed treatment regimens for chronic myeloid leukemia (CML), with detailed instructions about primary treatment and follow-up treatment.
Regular Assessment of Patient-Reported Factors Related to QOL Recommended in Patients With CML
Researchers found relationships between illness uncertainty, self-perceived burden, and quality of life in patients with chronic myeloid leukemia.
ACE-27 Score Has Prognostic Potential in Chronic Phase Chronic Myeloid Leukemia
A retrospective review demonstrated that higher Adult Comorbidity Evaluation 27 scores are prognostic for poorer outcomes in patients with CML.
Treatment of CML With Tyrosine Kinase Inhibitors Associated With Risk of Vascular Adverse Events
A retrospective cohort study revealed the risk of long-term TKI-associated vascular adverse events for patients receiving nilotinib or dasatinib for CML, particularly as a first-line treatment.
Ankle-Brachial Index, Cardiac Ankle Vascular Index May Indicate Risk of Cardiovascular AEs in Patients With CML Taking TKIs
A retrospective analysis of data identified predictors of cardiac adverse events in patients with CML undergoing treatment with tyrosine kinase inhibitors.
Algorithm Assesses Risk of Major Adverse Cardiovascular Events in TKI-Treated CML
Researchers sought to determine the accuracy of established cardiovascular assessment tools in predicting risk of CV events in patients with CML receiving TKIs.
- Loading...
Loading...
Next post in Chronic Myeloid Leukemia
Loading... 
Loading...